Commerce Bank lifted its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 4.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 215,337 shares of the medical research company’s stock after acquiring an additional 8,388 shares during the quarter. Commerce Bank’s holdings in Amgen were worth $44,637,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also bought and sold shares of the company. Kwmg LLC acquired a new position in shares of Amgen during the 2nd quarter valued at $108,000. Mainstay Capital Management LLC ADV acquired a new position in shares of Amgen during the 2nd quarter valued at $111,000. Polaris Greystone Financial Group LLC acquired a new position in shares of Amgen during the 3rd quarter valued at $166,000. Dixon Hubard Feinour & Brown Inc. VA acquired a new position in shares of Amgen during the 2nd quarter valued at $200,000. Finally, Family Firm Inc. acquired a new position in Amgen in the 2nd quarter worth $202,000. Institutional investors and hedge funds own 82.37% of the company’s stock.
A number of brokerages have commented on AMGN. JPMorgan Chase & Co. boosted their price objective on shares of Amgen from $191.00 to $192.00 and gave the stock a “neutral” rating in a report on Friday, July 27th. Jefferies Financial Group reiterated a “buy” rating and issued a $200.00 price objective on shares of Amgen in a report on Monday, July 16th. BidaskClub lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 19th. Goldman Sachs Group reiterated a “buy” rating and issued a $221.00 price objective on shares of Amgen in a report on Wednesday, October 31st. Finally, Royal Bank of Canada set a $193.00 price objective on shares of Amgen and gave the stock a “buy” rating in a report on Friday, July 27th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have issued a buy rating to the company. Amgen presently has an average rating of “Hold” and a consensus price target of $204.55.
Shares of Amgen stock opened at $193.16 on Friday. The stock has a market capitalization of $125.93 billion, a PE ratio of 15.35, a P/E/G ratio of 2.05 and a beta of 1.37. The company has a current ratio of 3.08, a quick ratio of 2.84 and a debt-to-equity ratio of 2.05. Amgen, Inc. has a 1 year low of $163.31 and a 1 year high of $210.19.
Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, October 30th. The medical research company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.45 by $0.24. The business had revenue of $5.90 billion for the quarter, compared to analyst estimates of $5.78 billion. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.27 EPS. Sell-side analysts forecast that Amgen, Inc. will post 14.24 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 7th. Stockholders of record on Friday, November 16th will be paid a $1.32 dividend. The ex-dividend date is Thursday, November 15th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.73%. Amgen’s dividend payout ratio (DPR) is presently 41.97%.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/11/10/commerce-bank-acquires-8388-shares-of-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Further Reading: What are the benefits of buying treasury bonds?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.